Barriers to the Collaboration Between Hematologists and Palliative Care Teams on Relapse or Refractory Leukemia and Malignant Lymphoma Patients’ Care

Abstract

Background:

Palliative care service (PCS) has been shown to be utilized less in patients with leukemia and malignant lymphoma than in those with solid tumors. Previous studies have suggested hematologists’ limited awareness of PCS as one of the reason for low PCS referral in hematology. However, little is known about such an awareness and potential barriers to collaboration between hematologists and PCS.

Aim:

The present study aimed to assess ematologists and palliative care specialists’ perception about the roles of the hospital-based palliative care team (HPCT) and the barriers to collaboration between hematologists and palliative care teams on relapse or refractory leukemia and malignant lymphoma patients’ care

Materials and Methods:

A qualitative study was conducted using semistructured interviews with hematologists and palliative care specialists recruited from a hospital that provides hematology and palliative care by the HPCT. Data were evaluated via content analysis.

Results:

The study included 11 hematologists and 10 palliative care specialists. Our results revealed that they shared many common perceptions about the roles and expectations of the HPCT. Additionally, 7 categories of barriers to collaboration were identified, including not feeling the need to refer, the difficulty in referral timing, the lack of aggressive approach, the negative image of the HPCT, the need for hematologic malignancy-oriented management, the lack of communication, and others.

Conclusion:

We have identified hematologists’ and palliative care specialists’ perceptions of the HPCT’s roles and the barriers to their collaboration. A better understanding of such barriers may lead to effective collaboration between hematologists and the HPCT.

Keywords

palliative care communication barriers referral and consultation leukemia lymphoma palliative care team

Get full access to this article

View all access options for this article.

References

Coiffier

Thieblemont

Van Den Neste

. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–2045.

Mandelli

Vignetti

Suciu

. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009;27(32):5397–5403.

Miyawaki

Sakamaki

Ohtake

. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. Cancer. 2005;104(12):2726–2734.

Pfreundschuh

Kuhnt

Trumper

. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–1022.

Howell

Roman

Cox

. Destined to die in hospital? Systematic review and meta-analysis of place of death in haematological malignancy. BMC Palliat Care. 2010;9:9.

Alt-Epping

Wulf

Nauck

. Palliative care for patients with hematological malignancies-a case series. Ann Hematol. 2011;90(5):613–615.

Cheng

H-WB

C-W

Chan

K-Y

. End-of-life characteristics and palliative care provision for elderly patients suffering from acute myeloid leukemia. Support Care Cancer. 2015;23(1):111–116.

Stalfelt

Brodin

Pettersson

Eklöf

. The final phase in acute myeloid leukaemia (AML). A study on bleeding, infection and pain. Leuk Res. 2003;27(6):481–488.

Brant

Beck

Dudley

Cobb

Pepper

Miaskowski

. Symptom trajectories in posttreatment cancer survivors. Cancer Nurs. 2011;34(1):67–77.

10.

Guidance on Cancer Services-Improving Outcomes in Haematological Cancers The Manual. London: National Institute for Clinical Excellence; 2003.

11.

Howell

Shellens

Roman

Garry

Patmore

Howard

. Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med. 2011;25(6):630–641.

12.

Maddocks

Bentley

Sheedy

. Quality of life issues in patients dying from haematological diseases. Ann Acad Med Singapore. 1994;23(2):244–248.

13.

Hui

Kim

Kwon

. Access to palliative care among patients treated at a comprehensive cancer center. Oncologist. 2012;17(12):1574–1580.

14.

Fadul

Elsayem

Palmer

Zhang

Braiteh

Bruera

. Predictors of access to palliative care services among patients who died at a Comprehensive Cancer Center. J Palliat Med. 2007;10(5):1146–1152.

15.

Fadul

El Osta

Dalal

Poulter

Bruera

. Comparison of symptom burden among patients referred to palliative care with hematologic malignancies versus those with solid tumors. J Palliat Med. 2008;11(3):422–427.

16.

McGrath

Holewa

. Missed opportunities: nursing insights on end-of-life care for haematology patients. Int J Nurs Pract. 2006;12(5):295–301.

17.

Auret

Bulsara

Joske

. Australasian haematologist referral patterns to palliative care: lack of consensus on when and why. Intern Med. 2003;33(12):566–571.

18.

Krippendorff

. Content Analysis: An Introduction to its Methodolgy (2nd ed.). Thousand Oaks, CA: Sage; 2004.

19.

Hosaka

Aoki

Ichikawa

. Emotional states of patients with hematological malignancies: preliminary study. Jpn J Clin Oncol. 1994;24(4):186–190.

20.

Zimmermann

Yuen

Mischitelle

. Symptom burden and supportive care in patients with acute leukemia. Leuk Res. 2013;37(7):731–736.

21.

Chang

Hwang

Feuerman

Kasimis

. Symptom and quality of life survey of medical oncology patients at a veterans affairs medical center: a role for symptom assessment. Cancer. 2000;88(5):1175–1183.

22.

O’Connor

Weir

Butcher

. Pain in patients attending a specialist cancer service: prevalence and association with emotional distress. J Pain Symptom Manage. 2012;43(1):29–38.

23.

Zimmermann

Rydall

. Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer. J Clin Oncol. 2010;28(18):3084–3089.

24.

Sasaki

The latest research trends in the field of basic and clinical hematological malignancies: Chemotherapy side effects of anti-hen treatment clinical. Nihon Rinnsho ed, Tokyo, Japan: Tasaki ono; 2007:384–389.

25.

Elsayem

Swint

Fisch

. Palliative care inpatient service in a comprehensive cancer center: clinical and financial outcomes. J Clin Oncol. 2004;22(10):2008–2014.

26.

Rodin

Yuen

Mischitelle

. Traumatic stress in acute leukemia. Psychooncology. 2013;22(2):299–307.

27.

Manitta

Philip

JAM

Cole-Sinclair

. Palliative care and the hemato-oncological patient: can we live together? A review of the literature. J Palliat Med. 2010;13(8):1021–1025.

28.

Bakitas

Lyons

Hegel

. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA. 2009;302(7):741–749.

29.

Greer

Pirl

Jackson

. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol. 2012;30(4):394–400.

30.

Temel

Greer

Admane

. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol. 2011;29(17):2319–2326.

31.

Ansell

Howell

Garry

. What determines referral of UK patients with haematological malignancies to palliative care services? An exploratory study using hospital records. Palliat Med. 2007;21(6):487–492.

32.

Chung

Lyckholm

Smith

. Palliative care in BMT. Bone Marrow Transplant. 2009;43(4):265–273.

33.

Epstein

Goldberg

Meier

. Palliative care and hematologic oncology: the promise of collaboration. Blood Rev. 2012;26(6):233–239.

34.

McGrath

Holewa

. Special considerations for haematology patients in relation to end-of-life care: Australian findings. Eur J Cancer Care. 2007;16(2):164–171.

35.

Chen

Yee

Jr . Improving primary care-specialty care communication: lessons from San Francisco’s safety net: comment on “Referral and consultation communication between primary care and specialist physicians”. Arch Intern Med. 2011;171(1):65–67.

36.

Kataoka

Ohno

Sagara

. Team approach to providing the multidisciplinary medical treatment derived by the patients and their family. Breast Cancer. 2005;12(1):21–25.

37.

Bahrami

Paul

. How do nurses assess quality of life of cancer patients in oncology wards and palliative settings? Eur J Oncol Nurs. 2012;16(3):212–219.

38.

Miyashita

Sanjo

Morita

. Barriers to providing palliative care and priorities for future actions to advance palliative care in Japan: a nationwide expert opinion survey. J Palliat Med. 2007;10(2):390–399.

39.

Rhondali

Burt

Wittenberg-Lyles

Bruera

Dalal

. Medical oncologists’ perception of palliative care programs and the impact of name change to supportive care on communication with patients during the referral process. A qualitative study. Palliat Support Care. 2013;11(5):397–404.

40.

Matsuda

Shibata

. The japan cancer surveillance research group. Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the monitoring of cancer incidence in Japan (MCIJ) Project. J Clin Oncol. 2013;44(4):388–396.

41.

Sasahara

Miyashita

Umeda

. Multiple evaluation of a hospital-based palliative care consultation team in a university hospital: activities, patient outcome, and referring staff’s view. Palliat Support Care. 2010;8(1):49–57.